What 199 Biotechnologies does

199 Biotechnologies is a translational biotech company founded in 2023 by Boris Djordjevic and headquartered in Singapore (registered as 199 Biotechnologies (SG) Pte Ltd), with operational offices in London and Hong Kong. It develops an integrated healthspan-extension platform built on epigenetic reprogramming science, organized into three program rails: (1) E-ON-001, a cancer reprogramming therapy applying engineered Yamanaka-factor variants (Oct4, Sox2, Klf4, c-Myc) to rewrite glioblastoma cell behavior, reduce invasiveness, and reactivate natural cell death while preserving healthy tissue (currently ~70% through preclinical efficacy); (2) PCC1 (Procyanidin C1), a senolytic polyphenol compound isolated from grape seeds that selectively clears senescent cells and demonstrated 64.2% lifespan extension in mice; and (3) AgeQuant, a commercially live diagnostics platform delivering NAD+, senescence marker, and microplastics biomarker panels at roughly 10x lower cost than traditional labs with next-day turnaround.

The company's core technical thesis is that cancer and aging are both driven by epigenetic damage that locks cells into destructive programs, and that partial reprogramming — brief exposure to reprogramming factors that restores youthful cellular function without erasing cell identity — can redirect cells back to healthier programs rather than destroying them. It has filed patent claims covering engineered reprogramming factors, delivery methods, and diagnostic panels to protect this approach. The leadership team includes Founder & CEO Boris Djordjevic, CTO Dr. Qinghua Lyu (drug development, senolytic programs), COO Zico Yip (operations, fundraising), CSO Emad Moeendarbary, and strategic advisors Antonia Schultze-Mosgau and Dr. Avi Roy (Oxford biomedical scientist and president of the Biogerontology Research Foundation).

199 Biotechnologies' near-term monetization comes from a hybrid model combining AgeQuant diagnostic testing sales, monthly and one-time donation tiers ($10–$100/month recurring and $25–$100 one-time), and planned direct-to-consumer online sales of PCC1 once launched. Go-to-market is primarily direct-to-consumer and self-serve via the company's website (199.bio), supplemented by dedicated partnership, research collaboration, and investor relations inquiry channels targeting strategic licensing, academic collaborations, and clinical trial recruitment. The company is privately held with no parent or subsidiary relationships and has not disclosed external institutional investors beyond the September 2024 funding round of approximately $7.02M.

Name

199 Biotechnologies

Legal name

199 Biotechnologies (SG) Pte Ltd

Website

https://199.bio

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

199 Biotechnologies is a Singapore-headquartered biotech (with offices in London and Hong Kong) developing an epigenetic reprogramming platform spanning E-ON-001 cancer therapy, PCC1 senolytic polyphenol, and the AgeQuant affordable biomarker diagnostics platform for oncology and longevity consumers.

Ownership category

akta.pro rank

Product category

Longevity Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Medical Laboratories (621511)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

akta.pro secondary industries

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)

Keywords

• Epigenetic reprogramming therapies
• Senolytic polyphenol compounds
• Cancer cell reprogramming
• Longevity biomarker diagnostics
• Healthspan extension research

Headquarters

HQ city

England

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Monthly Subscriptions: Monthly donation/subscription tiers ranging from $10/month (Friend) to $100/month (Founder) suggest a recurring revenue model through monthly supporters.
2. Product Sales (Senolytics):
3. Diagnostic Testing Services: AgeQuant diagnostic platform provides biomarker testing services to consumers and potentially healthcare providers, generating revenue from testing services.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

199 Biotechnologies is a translational biotech research lab developing epigenetic reprogramming therapies and diagnostics. Its three core offerings are E-ON-001, a cancer reprogramming therapy for glioblastoma; PCC1 (Procyanidin C1), a senolytic polyphenol compound for clearing senescent cells; and AgeQuant, a low-cost biomarker diagnostics platform delivering panels on NAD+, senescence markers, and microplastics at 10x lower cost than traditional labs.

Product overview

199 Biotechnologies operates as a platform company with three integrated rails: cancer reprogramming (E-ON-001 therapy), senolytics (PCC1 polyphenol compound), and diagnostics (AgeQuant platform). The platform is unified by epigenetic reprogramming science—E-ON-001 applies reprogramming factors to rewrite malignant cell behavior, PCC1 clears senescent cells to improve healthspan, and AgeQuant provides real-time biomarker readouts to measure intervention outcomes at 10x reduced cost. Together, these products form a comprehensive healthspan extension platform.

Differentiator

Problem solved

Functional benefit

Products and services

• E-ON-001 Cancer reprogramming therapy that rewrites malignant cell behavior at the epigenetic level using engineered reprogramming factors (Yamanaka factor variants) to reduce cancer cell invasiveness, prevent metastasis, halt uncontrolled growth, and reactivate natural cell death mechanisms without harming healthy tissue. Currently in preclinical development for glioblastoma.
• PCC1 (Procyanidin C1) Senolytic polyphenol compound isolated from grape seeds that selectively clears senescent cells and reduces SASP, demonstrating potency comparable to leading senolytic drugs with 64.2% lifespan extension in mice studies and a potentially safer natural compound profile.
• AgeQuant Longevity diagnostics platform delivering affordable biomarker testing (NAD+ levels, senescence markers, microplastics, and other key indicators) at 10x lower cost than traditional labs, with next-day results. Available directly to consumers.

Quantifiable outcome

• PCC1 demonstrated 64.2% lifespan extension in mice studies while safely clearing senescent cells
• +2 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• AgeX Therapeutics: AgeX Therapeutics develops cell-based and regenerative therapeutics for aging and age-related disease using pluripotent stem cell technology. Related in longevity therapeutic mission and shares some epigenetic reprogramming scientific heritage, though focused on different modalities.

Direct peers

• Unity Biotechnology: Unity Biotechnology is a clinical-stage senolytic drug developer pursuing senescent cell clearance therapies (UBX1325 etc.) for age-related eye disease. Directly comparable to 199 Biotechnologies' PCC1 senolytic program in modality and therapeutic approach.
• Life Biosciences: Life Biosciences is a partial reprogramming company pursuing cellular rejuvenation therapies for age-related disease. Directly comparable to 199 Biotechnologies in core modality (partial reprogramming) and indication strategy (multiple aging-related diseases).
• Retro Biosciences: Retro Biosciences is a Sam Altman-backed longevity company pursuing cellular reprogramming, autophagy, and plasma-inspired therapeutics. Directly competes in reprogramming-based rejuvenation with overlapping scientific foundation to 199 Biotechnologies.
• NewLimit: NewLimit is a partial reprogramming therapeutics company founded by Coinbase CEO Brian Armstrong, pursuing epigenetic reprogramming to treat age-related disease. Directly competes with 199 Biotechnologies in reprogramming factor technology and longevity applications.
• Altos Labs: Altos Labs is the most well-capitalized company pursuing partial reprogramming for cellular rejuvenation, with $3B+ raised and former Nobel laureate leadership. Directly competes with 199 Biotechnologies in the same modality (Yamanaka factor variants) for aging and disease applications.
• Turn Biotechnologies: Turn Biotechnologies develops mRNA-based epigenetic reprogramming therapies for age-related conditions including vision loss and skin regeneration. Comparable to 199 Biotechnologies in reprogramming modality and indication breadth across aging applications.
• Tally Health: Tally Health is a consumer longevity company offering epigenetic age testing and longevity interventions. Comparable to AgeQuant in direct-to-consumer longevity diagnostics business model and target demographic.
• InsideTracker: InsideTracker is a consumer longevity diagnostics company offering personalized biomarker testing and healthspan insights. Directly comparable to 199 Biotechnologies' AgeQuant platform in target customer (health-conscious longevity consumers) and business model (direct-to-consumer biomarker testing).
• Calico Life Sciences: Alphabet-backed Calico pursues aging biology and longevity therapeutics including cellular reprogramming approaches. Targets overlapping indications in age-related disease and competes for the same talent, capital, and scientific positioning as 199 Biotechnologies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/in/djordjevicboris
• Xx.com/199bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 199 Biotechnologies